Shop by goal

  • Metabolic Signalling
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • All compounds →
  • Popular compounds

  • BPC-157
  • TB-500
  • GHK-Cu
  • Retatrutide
  • Semaglutide
  • Ipamorelin
  • All bestsellers →
  • Research resources

  • Research Areas
  • Certificates of Analysis
  • Research Glossary
  • Compare Compounds
  • Peptide Guides
  • Delivery Guide
  • Track Order
  • Recently viewed

  • All peptide guides
  • Crypto Blog
  • How to Reconstitute
  • Reconstitution Calculator
  • How to Store
  • Research
  • Certificates of Analysis
  • Sign In
  • Create Account
  • My Account
  • My Orders
  • My Referrals
  • Log Out
  • Track Order
  • Refer a Friend
  • Follow us on Twitter/X
  • How-to guides

    CJC-1295 (without DAC): HGH / Somatropin research guide

    In short: CJC-1295 No DAC (Mod GRF 1-29), tetrasubstituted GHRH(1-29) analogue with DPP-IV resistance for acute pulsatile GH secretion research. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use, not for human or clinical use.

    Not medical advice. CJC-1295 (without DAC) is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

    CJC-1295 (without DAC) at a glance

    Compound type
    Research peptide
    Research category
    HGH / Somatropin
    Also known as
    Modified GRF 1-29, Mod GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF(1-29), ModGRF
    Molecular weight
    3,367.9 Da
    Research-grade purity
    >99% HPLC
    Evidence context
    Preclinical / research use only
    Regulatory status
    Not an approved medicine. Supplied as a research compound
    Last reviewed
    16 June 2026

    What to know first

  • Tetrasubstituted backbone provides DPP-IV resistance with 4-fold GH AUC increase over native GHRH(1-29)
  • Short 30-minute half-life produces acute pulsatile GH release mimicking endogenous GHRH kinetics
  • D-Ala2 substitution prevents dipeptidyl peptidase-IV cleavage at the N-terminus
  • Gln8 eliminates asparagine rearrangement and amide hydrolysis degradation pathways
  • Details and limits sit in the sections below. Research use only.

    What CJC-1295 (without DAC) is

    CJC-1295 without DAC (Modified GRF 1-29) is a short-acting tetrasubstituted GHRH analog that produces clean, physiologic growth hormone pulses without the week-long albumin-bound tail of the DAC version.

    One-paragraph overview from our research datasheet. Still scientific, but faster to read than the full mechanism list below.

    CJC-1295 No DAC (Mod GRF 1-29), tetrasubstituted GHRH(1-29) analogue with DPP-IV resistance for acute pulsatile GH secretion research.

    Research contexts

    Peer-reviewed papers discuss CJC-1295 (without DAC) in specific lab settings. The points below reflect research questions, not health claims.

    Research vs. personal use: Literature describes experiments in cells and animals. That is distinct from real-world use. Our products are for laboratory research only.

    Typical study contexts

  • Pituitary GH release patterns and metabolic readouts in animal research.
  • Comparisons between secretagogues and exogenous GH in model organisms.
  • Tetrasubstituted backbone provides DPP-IV resistance with 4-fold GH AUC increase over native GHRH(1-29).
  • Short 30-minute half-life produces acute pulsatile GH release mimicking endogenous GHRH kinetics.
  • D-Ala2 substitution prevents dipeptidyl peptidase-IV cleavage at the N-terminus.
  • Gln8 eliminates asparagine rearrangement and amide hydrolysis degradation pathways.
  • Why HGH / Somatropin research matters

    Growth-hormone axis peptides are studied for GH/IGF signalling in animals and cells. Focus stays on endocrine biology, not prescribing.

    Mechanisms (technical review)

    Our datasheet lists mechanistic themes from preclinical work. These are research endpoints, not health claims.

  • Tetrasubstituted backbone provides DPP-IV resistance with 4-fold GH AUC increase over native GHRH(1-29)
  • Short 30-minute half-life produces acute pulsatile GH release mimicking endogenous GHRH kinetics
  • D-Ala2 substitution prevents dipeptidyl peptidase-IV cleavage at the N-terminus
  • Gln8 eliminates asparagine rearrangement and amide hydrolysis degradation pathways
  • Leu27 prevents methionine oxidation enhancing peptide shelf stability
  • Synergistic GH amplification when co-administered with GHSR agonists (ipamorelin, GHRP-2, GHRP-6)
  • Lab handling & preparation

  • Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.. See the storage guide.
  • Research dosing context: Literature typically discusses 100–300 mcg subcutaneously. 1–3 times daily, typically pre-sleep and/or pre-training Functional t½ ≈ 30 min (vs. 6–8 days for DAC version); peak GH response within 15–30 min post-injection; GH pulse duration ~2 h. Often combined with GHSR agonists (e.g., ipamorelin 100–300 mcg) for synergistic pulsatile GH release. No albumin binding, entirely renal/hepatic clearance.
  • Preparation: Follow the reconstitution guide. Confirm volumes with the calculator.
  • Purity check: Use the COA reading guide and the published CJC-1295 (without DAC) Certificate of Analysis.
  • Common Questions People Are Asking

    What is CJC-1295 (without DAC)?

    CJC-1295 without DAC (also called Modified GRF 1-29) is a tetrasubstituted analogue of growth-hormone-releasing hormone, GHRH(1-29). Unlike the DAC version it has no albumin-binding tag, so it is short-acting (~30 min) and drives a physiologic, pulse-like release of growth hormone. Supplied as a lyophilised research-grade powder for laboratory use only.

    What does CJC-1295 do?

    In research models CJC-1295 binds the pituitary GHRH receptor and stimulates growth-hormone (and downstream IGF-1) release. The no-DAC form produces short, natural-shaped GH pulses; the DAC form sustains the signal for days. These are findings in cell and animal models; New-U supplies it for laboratory research only.

    Is CJC-1295 safe?

    In published animal studies CJC-1295 has generally been well tolerated, but there are no controlled human safety trials, so human safety is not established. It is a research compound, not a medicine; New-U makes no human-use claims and supplies it for laboratory research only.

    What is the difference between CJC-1295 and "Modified GRF 1-29"?

    They are the same peptide - a tetrasubstituted GHRH(1-29) without the DAC albumin-binding tag. "Modified GRF 1-29" is the older research name; "CJC-1295 without DAC" became the common marketplace name after the DAC version entered clinical development.

    Why is CJC-1295 no DAC usually stacked with ipamorelin?

    The two peptides activate different receptors (GHRHR vs GHSR) that synergise in GH release. Combining a GHRH analog with a ghrelin-receptor agonist produces a larger, cleaner GH pulse than either peptide alone - this is the standard research pairing in the literature.

    Does the short half-life mean it is worse than the DAC version?

    No - just different. The DAC version is for sustained elevation over days; the no-DAC version is for sharp, physiologic pulses. Which one is appropriate depends on the research question, not on which is "stronger".

    Is CJC-1295 (no DAC) the same as sermorelin or tesamorelin?

    They are related but not identical. All three are GHRH-based peptides that act on the pituitary GHRH receptor. Sermorelin is the unmodified GHRH(1-29) fragment; CJC-1295 no DAC (Modified GRF 1-29) is that same fragment with four stabilising substitutions that resist breakdown and raise GH output; tesamorelin is a separate stabilised GHRH analogue that reached approval for a specific indication. The no-DAC form is studied for its short, pulsatile profile. All are supplied here for laboratory research only.

    How should CJC-1295 no DAC be stored?

    Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The four stabilising substitutions make it more robust than native GHRH(1-29), but standard peptide handling still applies.

    What happens if you stop taking peptides?

    CJC-1295 (no DAC / Modified GRF 1-29) is a short-acting GHRH analogue that prompts the pituitary's own GH pulses. Because its half-life is minutes, the research indicates it clears almost immediately once administration stops, and the GH/IGF-1 axis returns toward its pre-treatment baseline without the suppression seen after exogenous HGH. Effects observed in a study simply lose their stimulus. These are research observations; CJC-1295 no DAC is supplied for laboratory research only and is not for human use.

    Is this page medical advice? Can I use CJC-1295 (without DAC) for my health?

    No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

    Where do I find CJC-1295 (without DAC) specs, purity certificates and pricing?

    Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

    Related peptide guides

    Other compounds researchers often read about alongside CJC-1295 (without DAC).

  • HGH 191 AA - companion guide
  • Tesamorelin - companion guide
  • Sermorelin - companion guide
  • HGH Fragment 176-191 - companion guide
  • Scientific sources & further reading

    Primary literature and registries for CJC-1295 (without DAC), plus mainstream coverage of the peptide category. Research use only - not medical advice.

    Databases & literature:

  • PubMed: peer-reviewed literature on CJC-1295
  • ClinicalTrials.gov: registered studies on CJC-1295
  • CJC-1295: Wikipedia
  • Peptides in the news:

  • WebMD: consumer health reference
  • BBC News: Health
  • CNN Health: “Peptides: what to know about the wellness trend”
  • Sky News: “Can peptides make America healthy again?”
  • Sky News: “Inside the exploding US peptides craze” (video)
  • Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”
  • Sky News Australia: “Backyard peptide boom sparks alarm” (video)
  • Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”
  • Ready to order? View full product specs

    Access concentration, batch info, variants, and current pricing on our shop.

    Also known as: Modified GRF 1-29, Mod GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF(1-29), ModGRF

    PRECISION. PURITY. PERFORMANCE.

    Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

    Shop

  • All research compounds
  • Price list
  • Where to buy peptides
  • Compare compounds
  • Compare vial sizes
  • Affiliate programme
  • Research

  • Peptide 101
  • Published COAs
  • Research areas
  • Research blog
  • How-to guides
  • Peptide guides
  • Research glossary
  • Support

  • Track your order
  • Contact us
  • Shipping & delivery
  • FAQ
  • Community forum
  • Customer reviews
  • Refund policy
  • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • PayPal
  • Cryptocurrency
  • Cash App
  • Card payments
  • Bank transfer (SEPA)
  • Paying with crypto
  • Live crypto prices
  • Shop by goal

  • Metabolic Signalling
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • Shop by compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Semaglutide
  • CJC-1295 (without DAC)
  • Ipamorelin
  • MOTS-C
  • All compounds →
  • Shop by region

  • United Kingdom
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • United States
  • Northern Ireland
  • Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    © 2026 New-U Research Compounds · new-u.io

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.